Shire PLC (LON:SHP)‘s stock had its “overweight” rating restated by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Wednesday. They currently have a GBX 6,300 ($76.91) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 38.80% from the stock’s previous close.
Several other equities analysts have also recently commented on SHP. Jefferies Group boosted their target price on shares of Shire PLC from GBX 6,050 ($73.86) to GBX 6,600 ($80.58) and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Deutsche Bank AG restated a “buy” rating and issued a GBX 6,000 ($73.25) target price on shares of Shire PLC in a research report on Monday, September 19th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research report on Wednesday, July 13th. Credit Suisse Group AG boosted their target price on shares of Shire PLC from GBX 5,000 ($61.04) to GBX 5,200 ($63.48) and gave the company an “outperform” rating in a research report on Wednesday, August 3rd. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the stock. Shire PLC has an average rating of “Buy” and an average target price of GBX 5,972.67 ($72.92).
Shire PLC (LON:SHP) opened at 4401.00 on Wednesday. The company has a 50-day moving average of GBX 5,031.96 and a 200 day moving average of GBX 4,675.31. The firm’s market cap is GBX 30.05 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.
In other news, insider Dominic Blakemore acquired 133 shares of Shire PLC stock in a transaction dated Friday, September 30th. The shares were bought at an average cost of GBX 5,010 ($61.16) per share, with a total value of £6,663.30 ($8,134.90).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.